ophthalmologytimes20 小时
Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
H.C. Wainwright将Outlook Therapeutics目标价下调至3美元
周二，H.C. Wainwright分析师Douglas Tsao将市值约6000万美元的小型生物科技公司Outlook Therapeutics Inc. (NASDAQ: OTLK ...
manilatimes23 小时
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment ...
In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.
Ascendiant Capital Markets Issues Pessimistic Forecast for Outlook Therapeutics (NASDAQ ...
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...
Outlook Therapeutics price target lowered to $3 from $30 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Outlook Therapeutics (OTLK) to $3 from $30 and keeps a Buy rating on ...
HC Wainwright Has Pessimistic Outlook of FULC Q1 Earnings
Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now ...